{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:11:02Z","timestamp":1790655062294,"version":"4.1.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chronic kidney disease (CKD) is often associated with chronic inflammation, influenced by the activation of mineralocorticoid receptors (MR). This review focuses on changes in immune cells and explores the important role that MR antagonists (MRAs), especially the new nonsteroidal MRA, finerenone, play in alleviating renal and cardiac injury by affecting the transformation of stimulated immune cells. We found that MR can promote the transformation of macrophages to M1 pro-inflammatory phenotype through IL-14 receptor and mitogen-activated protein kinase (MAPK)\u2013JNK. MR also activates helper T cells and reduces the generation of regulatory T cells by promoting the interaction between nuclear factor and activator protein-1, increasing the secretion of IL-2 and IL-18, increasing the expression of CD38 and CD69, especially the IL-17\/IL-23 axis. The above immune system changes jointly mediate inflammation leading to kidney damage and fibrosis. In addition, we propose that the NLRP3 inflammasome is associated with macrophage imbalance. Preclinical studies indicate that finerenone effectively reduces inflammation and prevents structural kidney damage without significant systemic blood pressure changes. These data will provide some ideas for further research in the field of immune mechanisms in future, and drug research targeting specific targets and channels may also become a new type of diagnostic and treatment measure.<\/jats:p>","DOI":"10.1007\/s11255-025-04530-1","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T07:52:38Z","timestamp":1746172358000},"page":"3299-3306","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Mineralocorticoid receptor antagonists promote renal immunosenescence"],"prefix":"10.1007","volume":"57","author":[{"given":"Qiao-Rui","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"key":"4530_CR1","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1053\/j.jrn.2011.10.020","volume":"22","author":"ND Vaziri","year":"2012","unstructured":"Vaziri ND, Pahl MV, Crum A, Norris K (2012) Effect of uremia on structure and function of immune system. J Ren Nutr 22:149\u2013156. https:\/\/doi.org\/10.1053\/j.jrn.2011.10.020","journal-title":"J Ren Nutr"},{"key":"4530_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41590-017-0006-x","volume":"19","author":"J Nikolich-\u017dugich","year":"2018","unstructured":"Nikolich-\u017dugich J (2018) The twilight of immunity: emerging concepts in aging of the immune system. Nat Immunol 19:10\u201319. https:\/\/doi.org\/10.1038\/s41590-017-0006-x","journal-title":"Nat Immunol"},{"key":"4530_CR3","doi-asserted-by":"publisher","first-page":"sfae235","DOI":"10.1093\/ckj\/sfae235","volume":"17","author":"Y Tang","year":"2024","unstructured":"Tang Y, Jiang J, Zhao Y, Du D (2024) Aging and chronic kidney disease: epidemiology, therapy, management and the role of immunity. Clin Kidney J 17:sfae235. https:\/\/doi.org\/10.1093\/ckj\/sfae235","journal-title":"Clin Kidney J"},{"key":"4530_CR4","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/nrneph.2013.110","volume":"9","author":"NJ Brown","year":"2013","unstructured":"Brown NJ (2013) Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis. Nat Rev Nephrol 9:459\u2013469. https:\/\/doi.org\/10.1038\/nrneph.2013.110","journal-title":"Nat Rev Nephrol"},{"key":"4530_CR5","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1161\/HYPERTENSIONAHA.114.04488","volume":"65","author":"J Bauersachs","year":"2015","unstructured":"Bauersachs J, Jaisser F, Toto R (2015) Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases. Hypertension 65:257\u2013263. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.114.04488","journal-title":"Hypertension"},{"key":"4530_CR6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s10741-005-2344-2","volume":"10","author":"Funder JW","year":"2005","unstructured":"Funder JW (2005) Mineralocorticoid receptors: distribution and activation. Heart Fail Rev 10:15\u201322. https:\/\/doi.org\/10.1007\/s10741-005-2344-2","journal-title":"Heart Fail Rev"},{"key":"4530_CR7","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.kint.2019.02.030","volume":"96","author":"J Barrera-Chimal","year":"2019","unstructured":"Barrera-Chimal J, Girerd S, Jaisser F (2019) Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis. Kidney Int 96:302\u2013319. https:\/\/doi.org\/10.1016\/j.kint.2019.02.030","journal-title":"Kidney Int"},{"key":"4530_CR8","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1161\/HYPERTENSIONAHA.120.16196","volume":"78","author":"J Kowalski","year":"2021","unstructured":"Kowalski J, Deng L, Suennen C, Koca D, Meral D, Bode C, Hein L, Lother A (2021) Eplerenone improves pulmonary vascular remodeling and hypertension by inhibition of the mineralocorticoid receptor in endothelial cells. Hypertension 78:456\u2013465. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.120.16196","journal-title":"Hypertension"},{"key":"4530_CR9","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1161\/HYPERTENSIONAHA.111.181123","volume":"59","author":"DA Kasal","year":"2012","unstructured":"Kasal DA, Barhoumi T, Li MW, Yamamoto N, Zdanovich E, Rehman A, Neves MF, Laurant P, Paradis P, Schiffrin EL (2012) T regulatory lymphocytes prevent aldosterone-induced vascular injury. Hypertension 59:324\u2013330. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.111.181123","journal-title":"Hypertension"},{"key":"4530_CR10","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s11906-010-0116-4","volume":"12","author":"Y Lu","year":"2010","unstructured":"Lu Y, Ku E, Campese VM (2010) Aldosterone in the pathogenesis of chronic kidney disease and proteinuria. Curr Hypertens Rep 12:303\u2013306. https:\/\/doi.org\/10.1007\/s11906-010-0116-4","journal-title":"Curr Hypertens Rep"},{"key":"4530_CR11","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.kint.2017.12.016","volume":"93","author":"J Barrera-Chimal","year":"2018","unstructured":"Barrera-Chimal J, Estrela GR, Lechner SM, Giraud S, El Moghrabi S, Kaaki S, Kolkhof P, Hauet T, Jaisser F (2018) The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling. Kidney Int 93:1344\u20131355. https:\/\/doi.org\/10.1016\/j.kint.2017.12.016","journal-title":"Kidney Int"},{"key":"4530_CR12","doi-asserted-by":"publisher","first-page":"e93513","DOI":"10.1371\/journal.pone.0093513","volume":"9","author":"T Doi","year":"2014","unstructured":"Doi T, Doi S, Nakashima A, Ueno T, Yokoyama Y, Kohno N, Masaki T (2014) Mizoribine ameliorates renal injury and hypertension along with the attenuation of renal caspase-1 expression in aldosterone-salt-treated rats. PLoS ONE 9:e93513. https:\/\/doi.org\/10.1371\/journal.pone.0093513","journal-title":"PLoS ONE"},{"key":"4530_CR13","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.cmet.2008.04.002","volume":"7","author":"K Kang","year":"2008","unstructured":"Kang K, Reilly SM, Karabacak V, Gangl MR, Fitzgerald K, Hatano B, Lee C-H (2008) Adipocyte-derived Th2 cytokines and myeloid PPARdelta regulate macrophage polarization and insulin sensitivity. Cell Metab 7:485\u2013495. https:\/\/doi.org\/10.1016\/j.cmet.2008.04.002","journal-title":"Cell Metab"},{"key":"4530_CR14","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1038\/nature05894","volume":"447","author":"JI Odegaard","year":"2007","unstructured":"Odegaard JI, Ricardo-Gonzalez RR, Goforth MH, Morel CR, Subramanian V, Mukundan L, Red Eagle A, Vats D, Brombacher F, Ferrante AW, Chawla A (2007) Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 447:1116\u20131120. https:\/\/doi.org\/10.1038\/nature05894","journal-title":"Nature"},{"key":"4530_CR15","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1161\/ATVBAHA.115.307031","volume":"36","author":"J-Y Sun","year":"2016","unstructured":"Sun J-Y, Li C, Shen Z-X, Zhang W-C, Ai T-J, Du L-J, Zhang Y-Y, Yao G-F, Liu Y, Sun S, Naray-Fejes-Toth A, Fejes-Toth G, Peng Y, Chen M, Liu X, Tao J, Zhou B, Yu Y, Guo F, Du J, Duan S-Z (2016) Mineralocorticoid receptor deficiency in macrophages inhibits neointimal hyperplasia and suppresses macrophage inflammation through SGK1-AP1\/NF-\u03baB pathways. Arterioscler Thromb Vasc Biol 36:874\u2013885. https:\/\/doi.org\/10.1161\/ATVBAHA.115.307031","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"4530_CR16","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1530\/JOE-20-0161","volume":"246","author":"GSY Ong","year":"2020","unstructured":"Ong GSY, Cole TJ, Tesch GH, Morgan J, Dowling JK, Mansell A, Fuller PJ, Young MJ (2020) Novel mineralocorticoid receptor mechanisms regulate cardiac tissue inflammation in male mice. J Endocrinol 246:123\u2013134. https:\/\/doi.org\/10.1530\/JOE-20-0161","journal-title":"J Endocrinol"},{"key":"4530_CR17","doi-asserted-by":"publisher","first-page":"2310269","DOI":"10.1080\/08916934.2024.2310269","volume":"57","author":"S Xu","year":"2024","unstructured":"Xu S, Wang D, Tan L, Lu J (2024) The role of NLRP3 inflammasome in type 2 inflammation related diseases. Autoimmunity 57:2310269. https:\/\/doi.org\/10.1080\/08916934.2024.2310269","journal-title":"Autoimmunity"},{"key":"4530_CR18","doi-asserted-by":"publisher","first-page":"H2009","DOI":"10.1152\/ajpheart.00522.2007","volume":"293","author":"SA Cooper","year":"2007","unstructured":"Cooper SA, Whaley-Connell A, Habibi J, Wei Y, Lastra G, Manrique C, Stas S, Sowers JR (2007) Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance. Am J Physiol Heart Circ Physiol 293:H2009-2023. https:\/\/doi.org\/10.1152\/ajpheart.00522.2007","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"4530_CR19","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00018-023-04978-3","volume":"80","author":"Q Wu","year":"2023","unstructured":"Wu Q, Meng W, Zhu B, Chen X, Fu J, Zhao C, Liu G, Luo X, Lv Y, Zhao W, Wang F, Hu S, Zhang S (2023) VEGFC ameliorates salt-sensitive hypertension and hypertensive nephropathy by inhibiting NLRP3 inflammasome via activating VEGFR3-AMPK dependent autophagy pathway. Cell Mol Life Sci 80:327. https:\/\/doi.org\/10.1007\/s00018-023-04978-3","journal-title":"Cell Mol Life Sci"},{"key":"4530_CR20","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/ajh\/hpaa137","volume":"34","author":"NS Ferreira","year":"2021","unstructured":"Ferreira NS, Tostes RC, Paradis P, Schiffrin EL (2021) Aldosterone, inflammation, immune system, and hypertension. Am J Hypertens 34:15\u201327. https:\/\/doi.org\/10.1093\/ajh\/hpaa137","journal-title":"Am J Hypertens"},{"key":"4530_CR21","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1161\/CIRCRESAHA.116.310480","volume":"120","author":"X-N Sun","year":"2017","unstructured":"Sun X-N, Li C, Liu Y, Du L-J, Zeng M-R, Zheng X-J, Zhang W-C, Liu Y, Zhu M, Kong D, Zhou L, Lu L, Shen Z-X, Yi Y, Du L, Qin M, Liu X, Hua Z, Sun S, Yin H, Zhou B, Yu Y, Zhang Z, Duan S-Z (2017) T-cell mineralocorticoid receptor controls blood pressure by regulating interferon-gamma. Circ Res 120:1584\u20131597. https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.310480","journal-title":"Circ Res"},{"key":"4530_CR22","doi-asserted-by":"publisher","first-page":"191","DOI":"10.4049\/jimmunol.0802886","volume":"184","author":"AA Herrada","year":"2010","unstructured":"Herrada AA, Contreras FJ, Marini NP, Amador CA, Gonz\u00e1lez PA, Cort\u00e9s CM, Riedel CA, Carvajal CA, Figueroa F, Michea LF, Fardella CE, Kalergis AM (2010) Aldosterone promotes autoimmune damage by enhancing Th17-mediated immunity. J Immunol 184:191\u2013202. https:\/\/doi.org\/10.4049\/jimmunol.0802886","journal-title":"J Immunol"},{"key":"4530_CR23","doi-asserted-by":"publisher","first-page":"175723","DOI":"10.1016\/j.ejphar.2023.175723","volume":"949","author":"TMH Dourado","year":"2023","unstructured":"Dourado TMH, Assis VO, Awata WMC, de Mello MMB, C\u00e1rnio EC, Castro MM, Tirapelli CR (2023) Mineralocorticoid receptors contribute to ethanol-induced vascular hypercontractility through reactive oxygen species generation and up-regulation of cyclooxygenase 2. Eur J Pharmacol 949:175723. https:\/\/doi.org\/10.1016\/j.ejphar.2023.175723","journal-title":"Eur J Pharmacol"},{"key":"4530_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-024-03382-3","author":"TMH Dourado","year":"2024","unstructured":"Dourado TMH, Nascimento DC, Rosa MH, Assis VO, Pimenta GF, Alves-Filho JC, Tirapelli CR (2024) Mineralocorticoid receptor antagonism partially prevents dysfunction of T cell maturation in rats chronically treated with ethanol. Naunyn Schmiedebergs Arch Pharmacol. https:\/\/doi.org\/10.1007\/s00210-024-03382-3","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"4530_CR25","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1161\/HYPERTENSIONAHA.117.09070","volume":"70","author":"C Li","year":"2017","unstructured":"Li C, Sun X-N, Zeng M-R, Zheng X-J, Zhang Y-Y, Wan Q, Zhang W-C, Shi C, Du L-J, Ai T-J, Liu Y, Liu Y, Du L-L, Yi Y, Yu Y, Duan S-Z (2017) Mineralocorticoid receptor deficiency in T cells attenuates pressure overload-induced cardiac hypertrophy and dysfunction through modulating T-cell activation. Hypertension 70:137\u2013147. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.117.09070","journal-title":"Hypertension"},{"key":"4530_CR26","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1161\/HYPERTENSIONAHA.113.02883","volume":"63","author":"CA Amador","year":"2014","unstructured":"Amador CA, Barrientos V, Pe\u00f1a J, Herrada AA, Gonz\u00e1lez M, Vald\u00e9s S, Carrasco L, Alzamora R, Figueroa F, Kalergis AM, Michea L (2014) Spironolactone decreases DOCA-salt-induced organ damage by blocking the activation of T helper 17 and the downregulation of regulatory T lymphocytes. Hypertension 63:797\u2013803. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.113.02883","journal-title":"Hypertension"},{"key":"4530_CR27","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1161\/HYPERTENSIONAHA.113.02620","volume":"63","author":"CF Krebs","year":"2014","unstructured":"Krebs CF, Lange S, Niemann G, Rosendahl A, Lehners A, Meyer-Schwesinger C, Stahl RAK, Benndorf RA, Velden J, Paust H-J, Panzer U, Ehmke H, Wenzel UO (2014) Deficiency of the interleukin 17\/23 axis accelerates renal injury in mice with deoxycorticosterone acetate+angiotensin ii-induced hypertension. Hypertension 63:565\u2013571. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.113.02620","journal-title":"Hypertension"},{"key":"4530_CR28","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.immuni.2012.06.011","volume":"37","author":"X Zeng","year":"2012","unstructured":"Zeng X, Wei Y-L, Huang J, Newell EW, Yu H, Kidd BA, Kuhns MS, Waters RW, Davis MM, Weaver CT, Chien Y (2012) \u03b3\u03b4 T cells recognize a microbial encoded B cell antigen to initiate a rapid antigen-specific interleukin-17 response. Immunity 37:524\u2013534. https:\/\/doi.org\/10.1016\/j.immuni.2012.06.011","journal-title":"Immunity"},{"key":"4530_CR29","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1159\/000524940","volume":"53","author":"K Luettges","year":"2022","unstructured":"Luettges K, Bode M, Diemer JN, Schwanbeck J, Wirth EK, Klopfleisch R, Kappert K, Thiele A, Ritter D, Foryst-Ludwig A, Kolkhof P, Wenzel UO, Kintscher U (2022) Finerenone reduces renal ROR\u03b3t \u03b3\u03b4 T cells and protects against cardiorenal damage. Am J Nephrol 53:552\u2013564. https:\/\/doi.org\/10.1159\/000524940","journal-title":"Am J Nephrol"},{"key":"4530_CR30","doi-asserted-by":"publisher","first-page":"5931","DOI":"10.4049\/jimmunol.175.9.5931","volume":"175","author":"LK Teixeira","year":"2005","unstructured":"Teixeira LK, Fonseca BPF, Vieira-de-Abreu A, Barboza BA, Robbs BK, Bozza PT, Viola JPB (2005) IFN-gamma production by CD8+ T cells depends on NFAT1 transcription factor and regulates Th differentiation. J Immunol 175:5931\u20135939. https:\/\/doi.org\/10.4049\/jimmunol.175.9.5931","journal-title":"J Immunol"},{"key":"4530_CR31","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1161\/HYPERTENSIONAHA.114.04147","volume":"64","author":"DW Trott","year":"2014","unstructured":"Trott DW, Thabet SR, Kirabo A, Saleh MA, Itani H, Norlander AE, Wu J, Goldstein A, Arendshorst WJ, Madhur MS, Chen W, Li C-I, Shyr Y, Harrison DG (2014) Oligoclonal CD8+ T cells play a critical role in the development of hypertension. Hypertension 64:1108\u20131115. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.114.04147","journal-title":"Hypertension"},{"key":"4530_CR32","doi-asserted-by":"publisher","first-page":"866","DOI":"10.3238\/arztebl.2010.0866","volume":"107","author":"RE Schmieder","year":"2010","unstructured":"Schmieder RE (2010) End organ damage in hypertension. Dtsch Arztebl Int 107:866\u2013873. https:\/\/doi.org\/10.3238\/arztebl.2010.0866","journal-title":"Dtsch Arztebl Int"},{"key":"4530_CR33","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1172\/JCI66882","volume":"123","author":"DH Ellison","year":"2013","unstructured":"Ellison DH (2013) Ubiquitylation and the pathogenesis of hypertension. J Clin Invest 123:546\u2013548. https:\/\/doi.org\/10.1172\/JCI66882","journal-title":"J Clin Invest"},{"key":"4530_CR34","doi-asserted-by":"publisher","first-page":"e0141288","DOI":"10.1371\/journal.pone.0141288","volume":"10","author":"RCM Berger","year":"2015","unstructured":"Berger RCM, Vassallo PF, Crajoinas RD, Oliveira ML, Martins FL, Nogueira BV, Motta-Santos D, Ara\u00fajo IB, Forechi L, Girardi ACC, Santos RAS, Mill JG (2015) Renal effects and underlying molecular mechanisms of long-term salt content diets in spontaneously hypertensive rats. PLoS ONE 10:e0141288. https:\/\/doi.org\/10.1371\/journal.pone.0141288","journal-title":"PLoS ONE"},{"key":"4530_CR35","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1161\/01.cir.98.23.2621","volume":"98","author":"HC Yu","year":"1998","unstructured":"Yu HC, Burrell LM, Black MJ, Wu LL, Dilley RJ, Cooper ME, Johnston CI (1998) Salt induces myocardial and renal fibrosis in normotensive and hypertensive rats. Circulation 98:2621\u20132628. https:\/\/doi.org\/10.1161\/01.cir.98.23.2621","journal-title":"Circulation"},{"key":"4530_CR36","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1161\/CIRCRESAHA.116.303697","volume":"116","author":"WG McMaster","year":"2015","unstructured":"McMaster WG, Kirabo A, Madhur MS, Harrison DG (2015) Inflammation, immunity, and hypertensive end-organ damage. Circ Res 116:1022\u20131033. https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.303697","journal-title":"Circ Res"},{"issue":"e92801","key":"4530_CR37","doi-asserted-by":"publisher","first-page":"92801","DOI":"10.1172\/jci.insight.92801","volume":"2","author":"AE Norlander","year":"2017","unstructured":"Norlander AE, Saleh MA, Pandey AK, Itani HA, Wu J, Xiao L, Kang J, Dale BL, Goleva SB, Laroumanie F, Du L, Harrison DG, Madhur MS (2017) A salt-sensing kinase in T lymphocytes, SGK1, drives hypertension and hypertensive end-organ damage. JCI Insight 2(e92801):92801. https:\/\/doi.org\/10.1172\/jci.insight.92801","journal-title":"JCI Insight"},{"key":"4530_CR38","doi-asserted-by":"publisher","first-page":"4402","DOI":"10.3390\/ijms25084402","volume":"25","author":"D Maaliki","year":"2024","unstructured":"Maaliki D, Itani M, Jarrah H, El-Mallah C, Ismail D, El Atie YE, Obeid O, Jaffa MA, Itani HA (2024) Dietary high salt intake exacerbates SGK1-mediated T cell pathogenicity in L-NAME\/high salt-induced hypertension. Int J Mol Sci 25:4402. https:\/\/doi.org\/10.3390\/ijms25084402","journal-title":"Int J Mol Sci"},{"key":"4530_CR39","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.yjmcc.2017.12.011","volume":"115","author":"M Buonafine","year":"2018","unstructured":"Buonafine M, Mart\u00ednez-Mart\u00ednez E, Amador C, Gravez B, Ibarrola J, Fern\u00e1ndez-Celis A, El Moghrabi S, Rossignol P, L\u00f3pez-Andr\u00e9s N, Jaisser F (2018) Neutrophil gelatinase-associated lipocalin from immune cells is mandatory for aldosterone-induced cardiac remodeling and inflammation. J Mol Cell Cardiol 115:32\u201338. https:\/\/doi.org\/10.1016\/j.yjmcc.2017.12.011","journal-title":"J Mol Cell Cardiol"},{"key":"4530_CR40","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1161\/HYPERTENSIONAHA.121.17712","volume":"79","author":"B Bonnard","year":"2022","unstructured":"Bonnard B, Ibarrola J, Lima-Posada I, Fern\u00e1ndez-Celis A, Durand M, Genty M, Lopez-Andr\u00e9s N, Jaisser F (2022) Neutrophil gelatinase-associated lipocalin from macrophages plays a critical role in renal fibrosis via the CCL5 (Chemokine Ligand 5)-Th2 cells-IL4 (Interleukin 4) pathway. Hypertension 79:352\u2013364. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.121.17712","journal-title":"Hypertension"},{"key":"4530_CR41","doi-asserted-by":"publisher","first-page":"3711","DOI":"10.3390\/ijms20153711","volume":"20","author":"A Duni","year":"2019","unstructured":"Duni A, Liakopoulos V, Roumeliotis S, Peschos D, Dounousi E (2019) Oxidative stress in the pathogenesis and evolution of chronic kidney disease: untangling Ariadne\u2019s thread. Int J Mol Sci 20:3711. https:\/\/doi.org\/10.3390\/ijms20153711","journal-title":"Int J Mol Sci"},{"key":"4530_CR42","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1056\/NEJM199811123392007","volume":"339","author":"G Remuzzi","year":"1998","unstructured":"Remuzzi G, Bertani T (1998) Pathophysiology of progressive nephropathies. N Engl J Med 339:1448\u20131456. https:\/\/doi.org\/10.1056\/NEJM199811123392007","journal-title":"N Engl J Med"},{"key":"4530_CR43","unstructured":"Toll-like receptor 4 contributes to vascular remodelling and endothelial dysfunction in angiotensin II-induced hypertension - PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/25712370\/. Accessed 20 Mar 2024"},{"key":"4530_CR44","doi-asserted-by":"publisher","first-page":"H2372","DOI":"10.1152\/ajpheart.00283.2011","volume":"301","author":"N L\u00f3pez-Andr\u00e9s","year":"2011","unstructured":"L\u00f3pez-Andr\u00e9s N, Martin-Fernandez B, Rossignol P, Zannad F, Lahera V, Fortuno MA, Cachofeiro V, D\u00edez J (2011) A role for cardiotrophin-1 in myocardial remodeling induced by aldosterone. Am J Physiol Heart Circ Physiol 301:H2372-2382. https:\/\/doi.org\/10.1152\/ajpheart.00283.2011","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"4530_CR45","first-page":"87","volume":"62","author":"M Miana","year":"2011","unstructured":"Miana M, de Las HN, Rodriguez C, Sanz-Rosa D, Martin-Fernandez B, Mezzano S, Lahera V, Martinez-Gonzalez J, Cachofeiro V (2011) Effect of eplerenone on hypertension-associated renal damage in rats: potential role of peroxisome proliferator activated receptor gamma (PPAR-\u03b3). J Physiol Pharmacol 62:87\u201394","journal-title":"J Physiol Pharmacol"},{"key":"4530_CR46","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.ijcard.2015.03.190","volume":"187","author":"C Echem","year":"2015","unstructured":"Echem C, Bomfim GF, Ceravolo GS, Oliveira MA, Santos-Eichler RA, Bechara LR, Veras MM, Saldiva PHN, Ferreira JC, Akamine EH, Fortes ZB, Dantas AP, de Carvalho MHC (2015) Anti-toll like receptor 4 (TLR4) therapy diminishes cardiac remodeling regardless of changes in blood pressure in spontaneously hypertensive rats (SHR). Int J Cardiol 187:243\u2013245. https:\/\/doi.org\/10.1016\/j.ijcard.2015.03.190","journal-title":"Int J Cardiol"},{"key":"4530_CR47","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1113\/JP277002","volume":"597","author":"S Koszegi","year":"2019","unstructured":"Koszegi S, Molnar A, Lenart L, Hodrea J, Balogh DB, Lakat T, Szkibinszkij E, Hosszu A, Sparding N, Genovese F, Wagner L, Vannay A, Szabo AJ, Fekete A (2019) RAAS inhibitors directly reduce diabetes-induced renal fibrosis via growth factor inhibition. J Physiol 597:193\u2013209. https:\/\/doi.org\/10.1113\/JP277002","journal-title":"J Physiol"},{"key":"4530_CR48","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/s41581-022-00590-z","volume":"18","author":"L Li","year":"2022","unstructured":"Li L, Fu H, Liu Y (2022) The fibrogenic niche in kidney fibrosis: components and mechanisms. Nat Rev Nephrol 18:545\u2013557. https:\/\/doi.org\/10.1038\/s41581-022-00590-z","journal-title":"Nat Rev Nephrol"},{"key":"4530_CR49","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/S0022-3565(25)22580-0","volume":"240","author":"M de Gasparo","year":"1987","unstructured":"de Gasparo M, Joss U, Ramjou\u00e9 HP, Whitebread SE, Haenni H, Schenkel L, Kraehenbuehl C, Biollaz M, Grob J, Schmidlin J (1987) Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther 240:650\u2013656","journal-title":"J Pharmacol Exp Ther"},{"key":"4530_CR50","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1124\/dmd.31.11.1448","volume":"31","author":"CS Cook","year":"2003","unstructured":"Cook CS, Berry LM, Bible RH, Hribar JD, Hajdu E, Liu NW (2003) Pharmacokinetics and metabolism of [14C]eplerenone after oral administration to humans. Drug Metab Dispos 31:1448\u20131455. https:\/\/doi.org\/10.1124\/dmd.31.11.1448","journal-title":"Drug Metab Dispos"},{"key":"4530_CR51","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1002\/cmdc.201200081","volume":"7","author":"L B\u00e4rfacker","year":"2012","unstructured":"B\u00e4rfacker L, Kuhl A, Hillisch A, Grosser R, Figueroa-P\u00e9rez S, Heckroth H, Nitsche A, Erg\u00fcden J-K, Gielen-Haertwig H, Schlemmer K-H, Mittendorf J, Paulsen H, Platzek J, Kolkhof P (2012) Discovery of BAY 94\u20138862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem 7:1385\u20131403. https:\/\/doi.org\/10.1002\/cmdc.201200081","journal-title":"ChemMedChem"},{"key":"4530_CR52","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","volume":"42","author":"R Agarwal","year":"2021","unstructured":"Agarwal R, Kolkhof P, Bakris G, Bauersachs J, Haller H, Wada T, Zannad F (2021) Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J 42:152\u2013161. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa736","journal-title":"Eur Heart J"},{"key":"4530_CR53","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","volume":"64","author":"P Kolkhof","year":"2014","unstructured":"Kolkhof P, Delbeck M, Kretschmer A, Steinke W, Hartmann E, B\u00e4rfacker L, Eitner F, Albrecht-K\u00fcpper B, Sch\u00e4fer S (2014) Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol 64:69\u201378. https:\/\/doi.org\/10.1097\/FJC.0000000000000091","journal-title":"J Cardiovasc Pharmacol"},{"key":"4530_CR54","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","volume":"34","author":"B Pitt","year":"2013","unstructured":"Pitt B, Kober L, Ponikowski P, Gheorghiade M, Filippatos G, Krum H, Nowack C, Kolkhof P, Kim S-Y, Zannad F (2013) Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94\u20138862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J 34:2453\u20132463. https:\/\/doi.org\/10.1093\/eurheartj\/eht187","journal-title":"Eur Heart J"},{"key":"4530_CR55","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1681\/ASN.2012111094","volume":"25","author":"LL Huang","year":"2014","unstructured":"Huang LL, Nikolic-Paterson DJ, Han Y, Ozols E, Ma FY, Young MJ, Tesch GH (2014) Myeloid mineralocorticoid receptor activation contributes to progressive kidney disease. J Am Soc Nephrol 25:2231\u20132240. https:\/\/doi.org\/10.1681\/ASN.2012111094","journal-title":"J Am Soc Nephrol"},{"key":"4530_CR56","doi-asserted-by":"publisher","first-page":"F1043","DOI":"10.1152\/ajprenal.00389.2012","volume":"304","author":"Y Han","year":"2013","unstructured":"Han Y, Ma FY, Tesch GH, Manthey CL, Nikolic-Paterson DJ (2013) Role of macrophages in the fibrotic phase of rat crescentic glomerulonephritis. Am J Physiol Renal Physiol 304:F1043-1053. https:\/\/doi.org\/10.1152\/ajprenal.00389.2012","journal-title":"Am J Physiol Renal Physiol"},{"key":"4530_CR57","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1161\/01.HYP.0000157408.43807.5a","volume":"45","author":"N Kobayashi","year":"2005","unstructured":"Kobayashi N, Hara K, Tojo A, Onozato ML, Honda T, Yoshida K, Mita S, Nakano S, Tsubokou Y, Matsuoka H (2005) Eplerenone shows renoprotective effect by reducing LOX-1-mediated adhesion molecule, PKCepsilon-MAPK-p90RSK, and Rho-kinase pathway. Hypertension 45:538\u2013544. https:\/\/doi.org\/10.1161\/01.HYP.0000157408.43807.5a","journal-title":"Hypertension"},{"key":"4530_CR58","doi-asserted-by":"publisher","first-page":"3350","DOI":"10.1172\/JCI41080","volume":"120","author":"MG Usher","year":"2010","unstructured":"Usher MG, Duan SZ, Ivaschenko CY, Frieler RA, Berger S, Sch\u00fctz G, Lumeng CN, Mortensen RM (2010) Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J Clin Invest 120:3350\u20133364. https:\/\/doi.org\/10.1172\/JCI41080","journal-title":"J Clin Invest"},{"key":"4530_CR59","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1172\/JCI20530","volume":"112","author":"R Kalluri","year":"2003","unstructured":"Kalluri R, Neilson EG (2003) Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 112:1776\u20131784. https:\/\/doi.org\/10.1172\/JCI20530","journal-title":"J Clin Invest"},{"key":"4530_CR60","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1038\/s41440-019-0211-0","volume":"42","author":"AS Bhuiyan","year":"2019","unstructured":"Bhuiyan AS, Rafiq K, Kobara H, Masaki T, Nakano D, Nishiyama A (2019) Effect of a novel nonsteroidal selective mineralocorticoid receptor antagonist, esaxerenone (CS-3150), on blood pressure and renal injury in high salt-treated type 2 diabetic mice. Hypertens Res 42:892\u2013902. https:\/\/doi.org\/10.1038\/s41440-019-0211-0","journal-title":"Hypertens Res"},{"key":"4530_CR61","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1161\/HYPERTENSIONAHA.116.08526","volume":"69","author":"L Lattenist","year":"2017","unstructured":"Lattenist L, Lechner SM, Messaoudi S, Le Mercier A, El Moghrabi S, Prince S, Bobadilla NA, Kolkhof P, Jaisser F, Barrera-Chimal J (2017) Nonsteroidal mineralocorticoid receptor antagonist finerenone protects against acute kidney injury-mediated chronic kidney disease. Hypertension 69:870\u2013878. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.116.08526","journal-title":"Hypertension"},{"key":"4530_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2369-3-1","volume":"3","author":"PW Sanders","year":"2002","unstructured":"Sanders PW, Wang P-X (2002) Activation of the Fas\/Fas ligand pathway in hypertensive renal disease in Dahl\/Rapp rats. BMC Nephrol 3:1. https:\/\/doi.org\/10.1186\/1471-2369-3-1","journal-title":"BMC Nephrol"},{"key":"4530_CR63","doi-asserted-by":"publisher","first-page":"e14038","DOI":"10.14814\/phy2.14038","volume":"7","author":"OK Travis","year":"2019","unstructured":"Travis OK, White D, Pierce WA, Ge Y, Stubbs CY, Spradley FT, Williams JM, Cornelius DC (2019) Chronic infusion of interleukin-17 promotes hypertension, activation of cytolytic natural killer cells, and vascular dysfunction in pregnant rats. Physiol Rep 7:e14038. https:\/\/doi.org\/10.14814\/phy2.14038","journal-title":"Physiol Rep"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04530-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-025-04530-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04530-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T06:56:33Z","timestamp":1766818593000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-025-04530-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":63,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["4530"],"URL":"https:\/\/doi.org\/10.1007\/s11255-025-04530-1","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,30]]},"assertion":[{"value":"23 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}